FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283399016> ?p ?o ?g. }

• W4283399016 endingPage "1631" @default.
• W4283399016 startingPage "1630" @default.
• W4283399016 abstract "Background: Philadelphia chromosome (Ph+) is the most common genetic abnormality of B-cell acute lymphoblastic leukemia (B-ALL), and also an independent prognostic high-risk marker. In addition to allogeneic hematopoietic stem cell transplantation, now tyrosine kinase inhibitor (TKI) has greatly improved the prognosis of patients with Ph+ B-cell ALL. Flumatinib is a kind of TKI originally developed in China and has been approved for chronic myeloid leukemia (CML). ABT-199, a selective Bcl-2 inhibitor, was effective in reducing leukemic burden in vitro and in vivo in B-ALL. However, there is no report about the anti-tumor effect of flumatinib in combination with Bcl-2 inhibitor in B-ALL. Aims: We explore the effect of flumatinib combined with Bcl-2 inhibitor on cell proliferation arrest and apoptosis in SUP-B15 human Ph+ B-cell ALL cells. Methods: CCK-8 assay was used to analyze the proliferation of SUP-B15 cells treated with flumatinib only, ABT-199 only, combination group, and vehicle control. All groups were treated for 48h at the same time. Apoptosis assay was performed with Annexin V staining following flow cytometry analysis. Expression of the apoptosis-associated gene and protein level was detected by real-time PCR and western blot, respectively. Results: Flumatinib and ABT-199 were sensitive to SUP-B15 in both single or combined treatment in a dose-dependent manner (Fig. 1A). The IC50 of flumatinib was 2.4uM, and ABT-199 5.5nM in the cells treated for 48 hours. Combination of various doses of flumatinib with 5.5nM (IC50) ABT-199 showed significantly higher proliferation arrest than that of either single drug, and CalcuSyn analysis showed a synergistic effect of the two drugs on the cell proliferation arrest (Fig. 1B). The combination of flumatinib with ABT-199 also significantly increased the apoptosis rate of SUP-B15 (39.2±1.2%) compared to either flumatinib (25.3±0.3%) or ABT-199 (10.6±0.7%) (p<0.05) (Fig. 1C). Furthermore, the combination treatment showed significantly higher expression of apoptosis-related proteins, Bax, Bad, Caspase-3 and Caspase-9 compared to either single drug in mRNA level by qPCR (p<0.05) (Fig. 1D) and protein level by western blot (Fig. 1E). Image:Summary/Conclusion: Both single drugs of flumatinib and ABT-199 are sensitive to SUP-B15 human Ph+ B-cell ALL cells. The combination of flumatinib with ABT-199 has a synergistic effect on cell proliferation arrest and apoptosis of the cells, revealing the potential of the novel combination for therapy of Ph+ B-cell ALL." @default.
• W4283399016 created "2022-06-25" @default.
• W4283399016 creator A5077299625 @default.
• W4283399016 creator A5082001473 @default.
• W4283399016 creator A5082011015 @default.
• W4283399016 date "2022-06-01" @default.
• W4283399016 modified "2023-09-23" @default.
• W4283399016 title "PB1749: APOPTOTIC EFFECT OF FLUMATINIB COMBINED WITH BCL2 INHIBITOR ON PH+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA" @default.
• W4283399016 doi "https://doi.org/10.1097/01.hs9.0000849852.81498.42" @default.
• W4283399016 hasPublicationYear "2022" @default.
• W4283399016 type Work @default.
• W4283399016 citedByCount "1" @default.
• W4283399016 countsByYear W42833990162022 @default.
• W4283399016 crossrefType "journal-article" @default.
• W4283399016 hasAuthorship W4283399016A5077299625 @default.
• W4283399016 hasAuthorship W4283399016A5082001473 @default.
• W4283399016 hasAuthorship W4283399016A5082011015 @default.
• W4283399016 hasBestOaLocation W42833990161 @default.
• W4283399016 hasConcept C121608353 @default.
• W4283399016 hasConcept C126322002 @default.
• W4283399016 hasConcept C153911025 @default.
• W4283399016 hasConcept C185592680 @default.
• W4283399016 hasConcept C190283241 @default.
• W4283399016 hasConcept C203014093 @default.
• W4283399016 hasConcept C2778461978 @default.
• W4283399016 hasConcept C2778729363 @default.
• W4283399016 hasConcept C2778820342 @default.
• W4283399016 hasConcept C2911091166 @default.
• W4283399016 hasConcept C502942594 @default.
• W4283399016 hasConcept C553184892 @default.
• W4283399016 hasConcept C55493867 @default.
• W4283399016 hasConcept C62112901 @default.
• W4283399016 hasConcept C71924100 @default.
• W4283399016 hasConcept C86803240 @default.
• W4283399016 hasConcept C88634738 @default.
• W4283399016 hasConceptScore W4283399016C121608353 @default.
• W4283399016 hasConceptScore W4283399016C126322002 @default.
• W4283399016 hasConceptScore W4283399016C153911025 @default.
• W4283399016 hasConceptScore W4283399016C185592680 @default.
• W4283399016 hasConceptScore W4283399016C190283241 @default.
• W4283399016 hasConceptScore W4283399016C203014093 @default.
• W4283399016 hasConceptScore W4283399016C2778461978 @default.
• W4283399016 hasConceptScore W4283399016C2778729363 @default.
• W4283399016 hasConceptScore W4283399016C2778820342 @default.
• W4283399016 hasConceptScore W4283399016C2911091166 @default.
• W4283399016 hasConceptScore W4283399016C502942594 @default.
• W4283399016 hasConceptScore W4283399016C553184892 @default.
• W4283399016 hasConceptScore W4283399016C55493867 @default.
• W4283399016 hasConceptScore W4283399016C62112901 @default.
• W4283399016 hasConceptScore W4283399016C71924100 @default.
• W4283399016 hasConceptScore W4283399016C86803240 @default.
• W4283399016 hasConceptScore W4283399016C88634738 @default.
• W4283399016 hasLocation W42833990161 @default.
• W4283399016 hasLocation W42833990162 @default.
• W4283399016 hasOpenAccess W4283399016 @default.
• W4283399016 hasPrimaryLocation W42833990161 @default.
• W4283399016 hasRelatedWork W2079966689 @default.
• W4283399016 hasRelatedWork W2357108276 @default.
• W4283399016 hasRelatedWork W2361963140 @default.
• W4283399016 hasRelatedWork W2363008779 @default.
• W4283399016 hasRelatedWork W2364791426 @default.
• W4283399016 hasRelatedWork W2367461549 @default.
• W4283399016 hasRelatedWork W2373572728 @default.
• W4283399016 hasRelatedWork W2377145381 @default.
• W4283399016 hasRelatedWork W2383837582 @default.
• W4283399016 hasRelatedWork W2390379877 @default.
• W4283399016 hasVolume "6" @default.
• W4283399016 isParatext "false" @default.
• W4283399016 isRetracted "false" @default.
• W4283399016 workType "article" @default.